PVRI Symposium Report 2025
June 26, 2025
I recently attended the PVRI Drug Discovery & Development Symposium 2025 in Amsterdam, held 16–17 June and regarded as the smaller of PVRI’s two Hlagship
I recently attended the PVRI Drug Discovery & Development Symposium 2025 in Amsterdam, held 16–17 June and regarded as the smaller of PVRI’s two Hlagship
The ERS Congress 2024 in Vienna attracted close to 20,000 delegates, both onsite and online, making it a vibrant and dynamic event focused on advancing
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients,
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Three new drugs for pulmonary hypertension have been approved by the US and/or EU regulatory authorities in the course of the last year: